Периндоприл в терапии артериальной гипертензии: повышаем комплаенс

Периндоприл в терапии артериальной гипертензии: повышаем комплаенс

Аникин Г.С., Минина Е.С., Андреевская Е.М. Периндоприл в терапии артериальной гипертензии: повышаем комплаенс. Системные гипертензии. 2015; 1: 83–86.

________________________________________________

Anikin G.S., Minina E.S., Andreevskaya E.M. Treatment with perindopril in patients with arterial hypertension: improving compliance. Systemic Hypertension. 2015; 1: 83–86.

Читать PDF

Аннотация

Проблема комплаенса актуальна при лечении пациентов, страдающих артериальной гипертензией. В обзоре представлены данные о механизмах повышения комплаенса в призме одного из наиболее исследованных препаратов периндоприла. Отражены аспекты как монотерапии периндоприлом, так и комбинации с индапамидом и амлодипином. Показаны преимущества фиксированных комбинаций. Отдельным аспектом удобства применения лекарственных средств служат диспергируемые формы. Показаны преимущества применения Престариума ORO – инновационной формы периндоприла, растворимой во рту.

Ключевые слова: артериальная гипертензия, приверженность лечению, периндоприл.

________________________________________________

The problem of the compliance is relevant in the treatment of patients with arterial hypertension. The review presents the data to identify mechanisms for improving the compliance in the context of one of the most studied drugs, such as – perindopril. We have indicated the aspects of perindopril monotherapy, as well as in combination with indapamide and amlodipine. We have showed the advantages of fixed combinations. The individual aspect of the easy medicine administration isdispersion form of the drug. This article shows the advantages of usage PrestariumR ORO – innovative form of perindopril, mouth dissolving tablets.

Key words: arterial hypertension, treatment compliance, perindopril.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Wong ND, Lopez VA, L'Italien G et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 2007; 167 (22): 2431–6.
2. Adherence to long-term therapies: evidence for action Geneva World Health Organization, 2003.
3. Strauch B, Petrák O, Zelinka T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31 (12): 2455–61.
4. Fox KM et al. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
5. PROGRESS Collaborative Group: Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24 (5): 475–84.
6. Brugts JJ, Boersma E, Deckers JW et al. Abstr. 5066: The treatment effect of perindopril is consistent in all patients with vascular disease: a combined analysis of three perindopril trials. Circulation 2008; 118: s1138.
7. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828–40.
8. Ferrari R et al. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed combination perindopril/amlodipine. Curr Med Research Opin 2008; 24 (12): 3543–57.
9. Sever P et al. Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): Evidence for the use of an amlodipine-perindopril combination. Medicographia 2009; 31: 43–50.
10. Jadhav U. Evaluation of efficacy and tolerability of perindopril and amlodipine combination in the management of patients with moderate-to-severe hypertension in India. Poster presentation at the 23rd Annual Scientific Meeting of the American Society of Hypertension. New Orleans, LA, May 14–17. J Clin Hypertens 2008. Abstr.
11. С.В.Мальчикова, Е.И.Тарловская. Диспергируемая лекарственная форма Престариума А в лечении артериальной гипертензии. Системные гипертензии. 2014; 4: 52–4. / S.V.Mal'chikova, E.I.Tarlovskaia. Dispergiruemaia lekarstvennaia forma Prestariuma A v lechenii arterial'noi gipertenzii. Sistemnye gipertenzii. 2014; 4: 52–4. [in Russian]

________________________________________________

1. Wong ND, Lopez VA, L'Italien G et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004. Arch Intern Med 2007; 167 (22): 2431–6.
2. Adherence to long-term therapies: evidence for action Geneva World Health Organization, 2003.
3. Strauch B, Petrák O, Zelinka T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31 (12): 2455–61.
4. Fox KM et al. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
5. PROGRESS Collaborative Group: Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003; 24 (5): 475–84.
6. Brugts JJ, Boersma E, Deckers JW et al. Abstr. 5066: The treatment effect of perindopril is consistent in all patients with vascular disease: a combined analysis of three perindopril trials. Circulation 2008; 118: s1138.
7. ADVANCE Collaborative Group. Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 828–40.
8. Ferrari R et al. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed combination perindopril/amlodipine. Curr Med Research Opin 2008; 24 (12): 3543–57.
9. Sever P et al. Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA): Evidence for the use of an amlodipine-perindopril combination. Medicographia 2009; 31: 43–50.
10. Jadhav U. Evaluation of efficacy and tolerability of perindopril and amlodipine combination in the management of patients with moderate-to-severe hypertension in India. Poster presentation at the 23rd Annual Scientific Meeting of the American Society of Hypertension. New Orleans, LA, May 14–17. J Clin Hypertens 2008. Abstr.
11. S.V.Mal'chikova, E.I.Tarlovskaia. Dispergiruemaia lekarstvennaia forma Prestariuma A v lechenii arterial'noi gipertenzii. Sistemnye gipertenzii. 2014; 4: 52–4. [in Russian]

Авторы

Г.С.Аникин*1,2, Е.С.Минина2, Е.М.Андреевская2

1 ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119992, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБУ Поликлиника №3 Управления делами Президента РФ. 129090, Россия, Москва, пер. Грохольский, д. 31
*medi321@mail.ru

________________________________________________

G.S.Anikin*1,2, E.S.Minina2, E.M.Andreevskaya2

1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119992, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2 Out-Patient Сlinic №3 of Administration of the President of Russian Federation of the Ministry of Health of the Russian Federation. 129090, Russian Federation, Moscow, per. Grokhol'skii, d. 31
*medi321@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.